<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010081576">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="bold" font="default" size="100%">Chesnais, Cédric</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Pion, Sébastien</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Boullé, C.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Gardon, Jacques</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Gardon-Wendel, N.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Fokom-Domgue, J.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Kamgno, J.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Boussinesq, Michel</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa</title>
        <secondary-title>EClinicalMedecine</secondary-title>
      </titles>
      <pages>100582 [7 ]</pages>
      <keywords>
        <keyword>CAMEROUN CENTRE</keyword>
        <keyword>CAMEROUN EST</keyword>
      </keywords>
      <dates>
        <year>2020</year>
      </dates>
      <call-num>fdi:010081576</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>EClinicalMedecine</full-title>
      </periodical>
      <isbn>2589-5370</isbn>
      <accession-num>ISI:000645903100010</accession-num>
      <electronic-resource-num>10.1016/j.eclinm.2020.100582</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010081576</url>
        </related-urls>
        <pdf-urls>
          <url>https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers21-04/010081576.pdf</url>
        </pdf-urls>
      </urls>
      <volume>28</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>Background:Implementation of onchocerciasis elimination programmes has been delayed in Central Africa because of the risk of ivermectin-related serious adverse events (SAEs) in individuals with high Loa loamicrofilarial densities (MFD). We developed the first statistical models enabling prediction of SAE risk in individuals with a given MFD. Methods:We used individual participant data from two trials conducted in loiasis-onchocerciasis co-endemicareas in Cameroon. among the 10 506 ivermectin-treated subjects included in the analysis, 38 (0¢36%) devel-oped an ivermectin-related SAE. To predict individual-level risk of SAE, we developed mixed multivariatelogistic models including subjects'sex, age, pre-treatment L loa and Mansonella perstans MFDs, and study region. Findings:The models predicted that regardless of sex, about 1% of people with 20 000L loa microfilariae permillilitre of blood (mf/mL), 10% of people with 50 000 mf/mL and about one third of those with 100 000 mf/mL will develop an SAE. For a given MFD, males have a three-fold higher risk of developing an SAE than females. Interpretation:By enabling the prediction of post-ivermectin SAE risk in communities with known distribution of L loa MFDs, our results can guide decisions on the choice of ivermectin-based treatment strategies.They also predict that 37 SAEs were prevented in 2015 by using a Test-and-Treat strategy in the Okola District of Cameroon.Funding:UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Institut de Recherche pour le Developpement; Mectizan Donation Program; Bill and Melinda Gates Foundation</abstract>
      <custom6>052MALTRA05 ; 050MEDECI</custom6>
      <custom1>UR233 / UR050</custom1>
      <custom7>Cameroun</custom7>
    </record>
  </records>
</xml>
